CE credit: For CE credit, you can access the test for this article, as well as additional JNMT
CE tests, online at https://www. snmmilearningcenter. org. Complete the test online no later …

The use of alpha emitting radiotherapeutics is increasing, with further growth expected due
to a number of clinical trials currently running involving new alpha emitters. However …

Abstract Radium-223 dichloride (Ra-223) is the first targeted alpha therapy approved for the
treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastasis …

Among all radium isotopes, at least two are used in nuclear medicine. Bayer-manufactured
223RaCl2 (trade name Xofigo) is applied for palliative care of bone metastasis …

The most recent survey (1) related to a-radiotherapy development showed that 27 molecules
labeled with 225Ac are presently under development, among which 13 have already …

Encouraging results from targeted α-therapy have received significant attention from
academia and industry. However, the limited availability of suitable radionuclides has …

Background: Alpha-particle-emitting radiotherapies are of great interest for the treatment of
disseminated cancer. Actinium-225 (225Ac) produces four α-particles through its decay and …

With a short particle range and high linear energy transfer, α-emitting radionuclides
demonstrate high cell-killing efficiencies. Even with the existence of numerous radionuclides …

Targeted α-therapy (TAT) is an emerging powerful tool treating late-stage cancers for which
therapeutic options are limited. At the core of TAT are targeted radiopharmaceuticals, where …

Background: As 225Ac-labeled radiopharmaceuticals continue to show promise as targeted
alpha therapeutics, there is a growing need to standardize quality control (QC) testing …